| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperlipidemias | D006949 | 73 associated lipids |
| Hyperparathyroidism, Secondary | D006962 | 4 associated lipids |
| Hypersensitivity | D006967 | 22 associated lipids |
| Hypersensitivity, Delayed | D006968 | 43 associated lipids |
| Hypersensitivity, Immediate | D006969 | 14 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Hypertension, Portal | D006975 | 12 associated lipids |
| Hypertension, Renal | D006977 | 9 associated lipids |
| Hypoglycemia | D007003 | 13 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Hypothermia | D007035 | 19 associated lipids |
| Ileal Neoplasms | D007078 | 2 associated lipids |
| Immunoblastic Lymphadenopathy | D007119 | 2 associated lipids |
| Immunologic Deficiency Syndromes | D007153 | 8 associated lipids |
| Immune System Diseases | D007154 | 3 associated lipids |
| Impetigo | D007169 | 3 associated lipids |
| Erectile Dysfunction | D007172 | 19 associated lipids |
| Inappropriate ADH Syndrome | D007177 | 4 associated lipids |
| Incontinentia Pigmenti | D007184 | 2 associated lipids |
| Infection | D007239 | 6 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |
| Dinçkan A et al. | Evaluation of the first 100 liver transplantations. | 2008 | Turk J Gastroenterol | pmid:18386237 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Troppmann C et al. | Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. | 2003 | Transplantation | pmid:12883205 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Cavaillé-Coll MW and Elashoff MR | Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. | 1998 | Transplantation | pmid:9448161 |
| Boleslawski E et al. | Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. | 2004 | Transplantation | pmid:15223897 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Bilolo KK et al. | Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. | 2003 | Transplantation | pmid:12811249 |
| Hashimoto T et al. | Treatment with FK506 prevents rejection of rat colon allografts. | 1994 | Transplantation | pmid:7516586 |
| Jain A et al. | Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. | 2014 | Transplantation | pmid:25285953 |
| Ericzon BG et al. | The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. | 1992 | Transplantation | pmid:1376501 |
| Gonwa TA et al. | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | 2001 | Transplantation | pmid:11773892 |
| Fisher RA et al. | A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9884248 |
| Solez K et al. | Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9884269 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Squifflet JP et al. | Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. | 2001 | Transplantation | pmid:11468536 |
| Jurcevic S et al. | A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. | 1998 | Transplantation | pmid:9603168 |
| Borrows R et al. | Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. | 2006 | Transplantation | pmid:16421488 |
| Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Shaffer D et al. | Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). | 1995 | Transplantation | pmid:7535958 |
| Andries S et al. | Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. | 2001 | Transplantation | pmid:11477351 |
| Taler SJ et al. | Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. | 1996 | Transplantation | pmid:8970613 |
| Naesens M et al. | Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. | 2008 | Transplantation | pmid:18431234 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Cantarovich D et al. | Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. | 2005 | Transplantation | pmid:15714172 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Inamura N et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. | 1988 | Transplantation | pmid:2447690 |
| Kuypers DR et al. | Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. | 2013 | Transplantation | pmid:23263559 |
| Shapiro R et al. | Tacrolimus in pediatric renal transplantation. | 1996 | Transplantation | pmid:8990356 |
| Ko S et al. | The pharmacokinetic benefits of newly developed liposome-incorporated FK506. | 1994 | Transplantation | pmid:7526494 |
| White M et al. | Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. | 2006 | Transplantation | pmid:17006323 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
| Foster RD et al. | Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. | 2003 | Transplantation | pmid:14508367 |